NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Efficacy of Using Interleukin-2 in Antiretroviral Naïve HIV Patients (ANRS119)

NCT00120185

CompletedPhase 2

Sponsor: French National Agency for Research on AIDS and Viral Hepatitis

Conditions: HIV Infections

Interventions: Interleukin-2

Countries: France

Interleukin-2 (IL-2) increases the number of CD4 cells in HIV-1 infected patients under highly active antiretroviral therapy (HAART) with a CD4 cell count over 200/mm3, but its activity in patients without antiretroviral therapy is unknown. This study will test the efficacy and safety of IL-2 in naïve patients with a CD4 count between 300 and 500/m3.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Adult patients with proven HIV-1-infection
* No prior exposition to antiretrovirals
* CD4 cell count between 300 and 500/mm3
* Signed written inform consent

Exclusion Criteria:

* Pregnancy

Locations (1)

Paris, France